Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers

Biological Psychiatry

Volumn 39, Issue 1, 1996, Pages 26-32

  Brauer, Lisa H ^a,b   De Wit, Harriet ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

d Amphetamine; Dopamine; Normal volunteers; Pimozide; Subjective effects

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; DOPAMINE; PIMOZIDE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EUPHORIA; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030027098     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(95)00110-7     Document Type: Article

References (38)

1. American Psychiatric Association (1987): Diagnostic and Statistical Manual of Mental Disorders, 3rd ed rev. Washington DC: American Psychiatric Association.
2. Anden NE, Butcher SG, Corrodi H, Fuxe K, Ungerstedt U (1970): Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol 11:303-313.
3. Angrist B, Lee HK, Gershon S (1974): The antagonism of amphetamine-induced symptomatology by a neuroleptic. Am J Psychiatry 131:817-819.
4. Angrist B, Corwin J, Bartlik B, Cooper T (1987): Early pharmacokinetics and clinical effects of oral d-amphetamine in normal subjects. Biol Psychiatry 22:1357-1368.
5. Chait LD, Uhlenhuth EH, Johanson CE (1986): The discriminative stimulus and subjective effects of d-amphetamine, phenmetrazine, and fenfluramine in humans. Psychopharmacology 89:301-306.
6. Colpaert FC, Niemegeers CJE, Janssen PAJ (1978): Discriminative stimulus properties of cocaine and d-amphetamine and antagonism by haloperidol: A comparative study. Neuropharmacology 17:937-942.
7. Ebert MH, Van Kammen DP, Murphy DL (1976): Plasma levels of amphetamine and behavioral response. In Gottschalk LA, Merlis S (eds), Pharmacokinetics of Psychoactive Drugs: Blood Levels and Clinical Response. New York: Spectrum Publications Inc, pp 157-169.
8. Fischman MW, Foltin RW (1991): Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict 86:1563-1570.
9. Folstein MF, Luria R (1973): Reliability, validity, and clinical applications of the visual analogue mood scale. Psychol Med 3:479-486.
10. Goudie AJ (1991): Discriminative stimulus properties of amphetamine, cathinone, and related agents. In Glennon RA, Jarbe TUC, Frankenheim J (eds), Drug Discrimination: Applications to Drug Abuse Research. National Institute on Drug Abuse Research Monograph No. 116. Washington DC: U.S. Government Printing Office, pp 45-60.
11. Griffiths RR, Bigelow GE, Henningfield JE (1980): Similarities in animal and human drug-taking behavior. In Mello NK (ed), Advances in Substance Abuse, vol 1. Greenwich, CT: JAI Press, pp 1-90.
12. Gunne LM, Anggard E, Jonsson LE (1972): Clinical trials with amphetamine-blocking drugs. Psychiatr Neurol Neurochir 75:225-226.
13. Haertzen CA, Hill HE, Belleville RE (1963): Development of the Addiction Research Center Inventory (ARCI): Selection of items that are sensitive to the effects of various drugs. Psychopharmacology 4:155-166.
14. Hindmarch I, Kerr JS, Sherwood N (1991): The effects of alcohol and other drugs on psychomotor performance and cognitive function. Alcohol Alcohol 26:71-79.
15. Ho BT, Huang J (1975): Role of dopamine in d-amphetamine-induced discriminative responding. Pharmacol Biochem Behav 3:1085-1092.
16. 3H-cis(z)-flupenthixol binding and on adenylate cyclase activity in vitro. Life Sci 23:551-556.
17. 3H-flupentixol to rat striatal dopamine receptors in vitro. Life Sci 28:563-569.
18. Hyttel J, Larsen JJ, Christensen AV, Arnt J (1985): Receptor-binding profiles of neuroleptics. In Casey DE, Chase TN, Christensen AV, Gerlach J (eds), Dyskinesia - Research and Treatment (Psychopharmacology Supplement 2). Berlin, Heidelberg: Springer-Verlag, pp 9-18.
19. Jacobs D, Silverstone T (1986): Dextroamphetamine-induced arousal in human subjects as a model for mania. Psychol Med 16:323-329.
20. Janssen PAJ, Niemegeers CJE, Schellekens KHL et al (1968): Pimozide, a chemically novel, highly potent and orally long-acting neuroleptic drug. Part 1: The comparative pharmacology of pimozide, haloperidol, and chlorpromazine. Arzneimittel-Forschung 3:261-279.
21. Johanson CE, Uhlenhuth E (1980): Drug preference and mood in humans: d-amphetamine. Psychopharmacology 71:275-279.
22. Jonsson LE (1972): Pharmacological blockade of amphetamine effects in amphetamine dependent subjects. Eur J Clin Pharmacol 4:206-211.
23. Keppel G (1982): Design and Analysis: A Researcher's Handbook, 2nd ed. Englewood Cliffs, NJ: Prentice-Hall Inc.
24. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971): Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245-258.
25. McMillan BA, Geman DC, Sanghera MK, Warnack W, Shore PA (1980): Pimozide: Delayed onset of action at rat striatal pre- and postsynaptic receptors. J Pharmacol Exp Ther 215:150-155.
26. McNair DM, Lorr M, Droppleman LF (1971): Profile of Mood States (Manual). San Francisco: Educational and Industrial Testing Service.
27. Nuotto EJ, Kortilla KT (1991): Evaluation of a new computerized psychomotor test battery: Effects of alcohol. Pharmacol Toxicol 68:360-365.
28. Physicians' Desk Reference, 45th ed (1991): Montvale, NJ: Medical Economics Company Inc.
29. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Spencer R, Avery GS (1976): Pimozide: A review of its pharmacological properties and therapeutic uses in psychiatry. Drugs 12:1-40.
30. Risner ME, Jones BE (1976): Role of noradrenergic and dopaminergic processes in amphetamine self-administration. Pharmacol Biochem Behav 5:477-482.
31. Schechter MD, Cook PG (1975): Dopaminergic mediation of the interoceptive cue produced by d-amphetamine in rats. Psychopharmacology 42:185-193.
32. Silverstone T, Fincham J, Wells B, Kyriakides M (1980): The effect of the dopamine receptor blocking drug pimozide on the stimulant and anorectic actions of dextroamphetamine in man. Neuropharmacology 19:1235-1237.
33. Stone BM (1984): Paper and pencil tests - sensitivity to psychotropic drugs. British J Clin Pharmacol 18:15S-20S.
34. Wechsler D (1958): The Measure and Appraisal of Adult Intelligence, 4th ed. Baltimore: Williams & Wilkins.
35. Wilson MC, Schuster CR (1972): The effects of chlorpromazine on psychomotor stimulant self-administration in the rhesus monkey. Psychopharmacology 26:115-126.
36. Woolverton WL, Kleven MS (1988): Multiple dopamine receptors and the behavioral effects of cocaine. In Clouet D, Asghar K, Brown R (eds), Mechanisms of Cocaine Abuse and Toxicity. National Institute on Drug Abuse Research Monograph No. 88, Washington DC: U.S. Government Printing Office, pp 160-184.
37. Yokel RA, Wise RA (1975): Increased lever pressing for amphetamine after pimozide in rats: Implications for a dopamine theory of reward. Science 187:547-549.
38. Yokel RA, Wise RA (1976): Attenuation of intravenous amphetamine reinforcement by central dopamine blockade in rats. Psychopharmacology 48:311-318.